Frontiers in Oncology (Jan 2022)
Isoalantolactone Enhances the Antitumor Activity of Doxorubicin by Inducing Reactive Oxygen Species and DNA Damage
- Fengjiao Wu,
- Fengjiao Wu,
- Fengjiao Wu,
- Rongrong Shao,
- Rongrong Shao,
- Rongrong Shao,
- Peisen Zheng,
- Peisen Zheng,
- Tingting Zhang,
- Tingting Zhang,
- Chenyu Qiu,
- Chenyu Qiu,
- Hehuan Sui,
- Hehuan Sui,
- Shaotang Li,
- Libo Jin,
- Huanle Pan,
- Xiance Jin,
- Peng Zou,
- Peng Zou,
- Peng Zou,
- Peng Zou,
- Ri Cui,
- Ri Cui,
- Ri Cui,
- Ri Cui,
- Congying Xie,
- Congying Xie
Affiliations
- Fengjiao Wu
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Fengjiao Wu
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Fengjiao Wu
- Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, China
- Rongrong Shao
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Rongrong Shao
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Rongrong Shao
- Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, China
- Peisen Zheng
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Peisen Zheng
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Tingting Zhang
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Tingting Zhang
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Chenyu Qiu
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Chenyu Qiu
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Hehuan Sui
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Hehuan Sui
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Shaotang Li
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Libo Jin
- Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, China
- Huanle Pan
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Xiance Jin
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Peng Zou
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Peng Zou
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Peng Zou
- Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, China
- Peng Zou
- Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, China
- Ri Cui
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Ri Cui
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- Ri Cui
- Wenzhou University-Wenzhou Medical University Collaborative Innovation Center of Biomedical, Wenzhou, China
- Ri Cui
- Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, China
- Congying Xie
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China
- Congying Xie
- Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- DOI
- https://doi.org/10.3389/fonc.2022.813854
- Journal volume & issue
-
Vol. 12
Abstract
Colon cancer is one of the most common cancer in the world. Doxorubicin (DOX) is a classical anti-tumor drug which widely used in treatment of cancers, however, high toxicity limited its further clinical application. Thus, it is urgent to find new drugs with low toxicity and high efficiency to treat colon cancer. Isoalantolactone (IATL), an isomeric sesquiterpene lactone isolated from the plant of inula helenium, has been reported to have anti-cancer activity against a variety of cancer cells. However, the function of IATL in colon cancer remains unclear. Here, we demonstrated that IATL inhibited colon cancer cell growth by increasing cellular reactive oxygen species (ROS) production. Further study showed that ROS accumulation contributed to DNA damage and JNK signaling pathway activation. In addition, we found that IATL markedly enhanced DOX-induced cell cytotoxicity in colon cancer cells. IATL in combination with DOX significantly increased the ROS production, induced DNA damage and activated JNK signaling pathway. Taken together, our data suggested that combined treatment with IATL and DOX may serve as a potential therapeutics for colon cancer.
Keywords
